The market size of the Global Minimal Residual Disease Market in the year 2021 is valued at 1.06 billion and is predicted to reach 3.73 billion by the year 2030 at an 15.18% CAGR during the forecast period.
Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years. The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.
The minimal residual disease market is segmented on the indication, detection, treatment method and treatment centres. Based on indication, the minimal residual disease market is divided into leukemia, acute lymphoblastic leukemia (All), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML, chronic myeloid leukemia (CML), Others, lymphoma, non-Hodgkin's lymphoma (NHL), marginal zone lymphoma, follicular lymphoma, peripheral t-cell lymphoma, mantle cell lymphoma, others, multiple myeloma (MM), solid tumor, and others. Based on the detection, the minimal residual disease market is divided into next-generation sequencing (NGS), flow cytometry, polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH) and others. Based on the treatment method, the minimal residual disease market is segmented into chemotherapy, stem cell transplant, cart cell therapy and others. Based on the treatment center, the minimal residual disease market is segmented into hospitals, oncology treatment centers, diagnostic centers & research institutions, speciality clinics and others.
Based on the detection, the next-generation segment is accounted as a major contributor to the minimal residual disease market.
The market's leading segment is the next generation. Next-generation sequencing is a technique for determining the sequence of DNA or RNA to analyze genetic changes linked with disease. It is also known as massively parallel sequencing since it allows the sequencing to select the sequencing of multiple DNA sequences simultaneously. The factors driving the growth of next-generation sequencing technology are rising cancer incidences worldwide, rising demand for next-generation sequencing services and applications in drug development, clinical procedures, precision medicine, and adoption of the most advanced next-generation sequencing technology.
The hospital pharmacy segment witnessed growth at a rapid rate.
Hospital pharmacy is predicted to be the fastest-growing segment. This is due to the high hospitalization rate of SMA. Because of the significant risk of respiratory difficulties and scoliosis, most patients are treated in hospitals. This can also be linked to higher capital requirements for performing clinical trials through contract research organizations (CROs) and the chance of drug failure during clinical trials.
The North American minimal residual disease market holds a significant regional revenue share.
The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.
Some major key players in the Minimal residual disease market are Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera Inc., NeoGenomics Laboratories, OPKO Health Inc., Sysmex Corporation